<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39085360</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>1mΨ influences the performance of various positive-stranded RNA virus-based replicons.</ArticleTitle><Pagination><StartPage>17634</StartPage><MedlinePgn>17634</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-68617-y</ELocationID><Abstract><AbstractText>Self-amplifying RNAs (saRNAs) are versatile vaccine platforms that take advantage of a viral RNA-dependent RNA polymerase (RdRp) to amplify the messenger RNA (mRNA) of an antigen of interest encoded within the backbone of the viral genome once inside the target cell. In recent years, more saRNA vaccines have been clinically tested with the hope of reducing the vaccination dose compared to the conventional mRNA approach. The use of N1-methyl-pseudouridine (1mΨ), which enhances RNA stability and reduces the innate immune response triggered by RNAs, is among the improvements included in the current mRNA vaccines. In the present study, we evaluated the effects of this modified nucleoside on various saRNA platforms based on different viruses. The results showed that different stages of the replication process were affected depending on the backbone virus. For TNCL, an insect virus of the Alphanodavirus genus, replication was impaired by poor recognition of viral RNA by RdRp. In contrast, the translation step was severely abrogated in coxsackievirus B3 (CVB3), a member of the Picornaviridae family. Finally, the effects of 1mΨ on Semliki forest virus (SFV), were not detrimental in in vitro studies, but no advantages were observed when immunogenicity was tested in vivo.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyazato</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noguchi</LastName><ForeName>Takafumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogawa</LastName><ForeName>Fumiyo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauzyah</LastName><ForeName>Yuzy</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebina</LastName><ForeName>Hirotaka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan. hebina@biken.osaka-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, Japan. hebina@biken.osaka-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan. hebina@biken.osaka-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Advanced Modalities and DDS (CAMaD), Osaka University, Suita, Osaka, Japan. hebina@biken.osaka-u.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, Japan. hebina@biken.osaka-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP223fa627002</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>1445-07-4</RegistryNumber><NameOfSubstance UI="D011560">Pseudouridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011560" MajorTopicYN="N">Pseudouridine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085102" MajorTopicYN="N">Positive-Strand RNA Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012672" MajorTopicYN="N">Semliki forest virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020871" MajorTopicYN="N">RNA Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Modified nucleosides</Keyword><Keyword MajorTopicYN="N">N1-Methyl-pseudouridine</Keyword><Keyword MajorTopicYN="N">Nodavirus</Keyword><Keyword MajorTopicYN="N">Replicons</Keyword><Keyword MajorTopicYN="N">Viral replication</Keyword></KeywordList><CoiStatement>P.M., T.N., F.O., T.S., Y.F., R.S., and H.E. are employed by BIKEN. H.E. holds a managerial position at BIKEN.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>31</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39085360</ArticleId><ArticleId IdType="pmc">PMC11292005</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-68617-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-68617-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Comes, J. D. G., Pijlman, G. P. &amp; Hick, T. A. H. Rise of the RNA machines—Self-amplification in mRNA vaccine design. Trends Biotechnol.41, 1417–1429. 10.1016/j.tibtech.2023.05.007 (2023). 10.1016/j.tibtech.2023.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2023.05.007</ArticleId><ArticleId IdType="pmc">PMC10266560</ArticleId><ArticleId IdType="pubmed">37328401</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong, C. et al. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells. Science243, 1188–1191. 10.1126/science.2922607 (1989). 10.1126/science.2922607</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.2922607</ArticleId><ArticleId IdType="pubmed">2922607</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, X. et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine12, 1510–1514. 10.1016/0264-410x(94)90074-4 (1994). 10.1016/0264-410x(94)90074-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410x(94)90074-4</ArticleId><ArticleId IdType="pubmed">7879415</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushko, P. et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology239, 389–401. 10.1006/viro.1997.8878 (1997). 10.1006/viro.1997.8878</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1997.8878</ArticleId><ArticleId IdType="pubmed">9434729</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel, A. B. et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther.26, 446–455. 10.1016/j.ymthe.2017.11.017 (2018). 10.1016/j.ymthe.2017.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.11.017</ArticleId><ArticleId IdType="pmc">PMC5835025</ArticleId><ArticleId IdType="pubmed">29275847</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom, K. Self-replicating RNA viruses for vaccine development against infectious diseases and cancer. Vaccines9, 187. 10.3390/vaccines9101187 (2021). 10.3390/vaccines9101187</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9101187</ArticleId><ArticleId IdType="pmc">PMC8541504</ArticleId><ArticleId IdType="pubmed">34696295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom, K. Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther.30, 771–784. 10.1038/s41417-022-00436-7 (2023). 10.1038/s41417-022-00436-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-022-00436-7</ArticleId><ArticleId IdType="pmc">PMC8853047</ArticleId><ArticleId IdType="pubmed">35169298</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney, A. K., Ip, S. &amp; Geall, A. J. An update on self-amplifying mRNA vaccine development. Vaccines9, 97. 10.3390/vaccines9020097 (2021). 10.3390/vaccines9020097</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9020097</ArticleId><ArticleId IdType="pmc">PMC7911542</ArticleId><ArticleId IdType="pubmed">33525396</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom, K., van den Berg, F. &amp; Arbuthnot, P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther.28, 117–129. 10.1038/s41434-020-00204-y (2021). 10.1038/s41434-020-00204-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-020-00204-y</ArticleId><ArticleId IdType="pmc">PMC7580817</ArticleId><ArticleId IdType="pubmed">33093657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom, K. Self-amplifying RNA viruses as RNA vaccines. Int. J. Mol. Sci.21, 130. 10.3390/ijms21145130 (2020).10.3390/ijms21145130</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21145130</ArticleId><ArticleId IdType="pmc">PMC7404065</ArticleId><ArticleId IdType="pubmed">32698494</ArticleId></ArticleIdList></Reference><Reference><Citation>Akahata, W. et al. Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study. Cell Rep. Med.4, 101134. 10.1016/j.xcrm.2023.101134 (2023). 10.1016/j.xcrm.2023.101134</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101134</ArticleId><ArticleId IdType="pmc">PMC10439244</ArticleId><ArticleId IdType="pubmed">37586325</ArticleId></ArticleIdList></Reference><Reference><Citation>Komdeur, F. L. et al. First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers. Mol. Ther.29, 611–625. 10.1016/j.ymthe.2020.11.002 (2021). 10.1016/j.ymthe.2020.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.11.002</ArticleId><ArticleId IdType="pmc">PMC7854293</ArticleId><ArticleId IdType="pubmed">33160073</ArticleId></ArticleIdList></Reference><Reference><Citation>Aliahmad, P., Miyake-Stoner, S. J., Geall, A. J. &amp; Wang, N. S. Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Ther.30, 785–793. 10.1038/s41417-022-00435-8 (2023). 10.1038/s41417-022-00435-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-022-00435-8</ArticleId><ArticleId IdType="pmc">PMC8861484</ArticleId><ArticleId IdType="pubmed">35194198</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahul Hameed, A. S. et al. ICTV virus taxonomy profile: Nodaviridae. J. Gen. Virol.100, 3–4. 10.1099/jgv.0.001170 (2019). 10.1099/jgv.0.001170</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001170</ArticleId><ArticleId IdType="pubmed">30431412</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter, P. A. &amp; Schneemann, A. Recent insights into the biology and biomedical applications of Flock House virus. Cell Mol. Life Sci.65, 2675–2687. 10.1007/s00018-008-8037-y (2008). 10.1007/s00018-008-8037-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-8037-y</ArticleId><ArticleId IdType="pmc">PMC2536769</ArticleId><ArticleId IdType="pubmed">18516498</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy, F. A., Scherer, W. F., Harrison, A. K., Dunne, H. W. &amp; Gary, G. W. Characterization of Nodamura virus, an arthropod transmissible picornavirus. Virology40, 1008–1021. 10.1016/0042-6822(70)90147-9 (1970). 10.1016/0042-6822(70)90147-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(70)90147-9</ArticleId><ArticleId IdType="pubmed">4194172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball, L. A., Amann, J. M. &amp; Garrett, B. K. Replication of nodamura virus after transfection of viral RNA into mammalian cells in culture. J. Virol.66, 2326–2334. 10.1128/JVI.66.4.2326-2334.1992 (1992). 10.1128/JVI.66.4.2326-2334.1992</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.66.4.2326-2334.1992</ArticleId><ArticleId IdType="pmc">PMC289028</ArticleId><ArticleId IdType="pubmed">1548765</ArticleId></ArticleIdList></Reference><Reference><Citation>Selling, B. H., Allison, R. F. &amp; Kaesberg, P. Genomic RNA of an insect virus directs synthesis of infectious virions in plants. Proc. Natl. Acad. Sci. U.S.A.87, 434–438. 10.1073/pnas.87.1.434 (1990). 10.1073/pnas.87.1.434</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.1.434</ArticleId><ArticleId IdType="pmc">PMC53278</ArticleId><ArticleId IdType="pubmed">2296598</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, B. D., Rueckert, R. R. &amp; Ahlquist, P. Complete replication of an animal virus and maintenance of expression vectors derived from it in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A.93, 9465–9470. 10.1073/pnas.93.18.9465 (1996). 10.1073/pnas.93.18.9465</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.18.9465</ArticleId><ArticleId IdType="pmc">PMC38451</ArticleId><ArticleId IdType="pubmed">8790353</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian, H., Zhang, Y., Yu, C. &amp; Wang, Y. Nanobiotechnology-enabled mRNA stabilization. Pharmaceutics15, 620. 10.3390/pharmaceutics15020620 (2023). 10.3390/pharmaceutics15020620</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15020620</ArticleId><ArticleId IdType="pmc">PMC9965532</ArticleId><ArticleId IdType="pubmed">36839942</ArticleId></ArticleIdList></Reference><Reference><Citation>Metkar, M., Pepin, C. S. &amp; Moore, M. J. Tailor made: The art of therapeutic mRNA design. Nat. Rev. Drug Discov.23, 67–83. 10.1038/s41573-023-00827-x (2024). 10.1038/s41573-023-00827-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00827-x</ArticleId><ArticleId IdType="pubmed">38030688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T. et al. Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo. iScience27, 109804. 10.1016/j.isci.2024.109804 (2024). 10.1016/j.isci.2024.109804</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.109804</ArticleId><ArticleId IdType="pmc">PMC11103379</ArticleId><ArticleId IdType="pubmed">38770138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko, K., Buckstein, M., Ni, H. &amp; Weissman, D. Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity23, 165–175. 10.1016/j.immuni.2005.06.008 (2005). 10.1016/j.immuni.2005.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.06.008</ArticleId><ArticleId IdType="pubmed">16111635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther.16, 1833–1840. 10.1038/mt.2008.200 (2008). 10.1038/mt.2008.200</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.200</ArticleId><ArticleId IdType="pmc">PMC2775451</ArticleId><ArticleId IdType="pubmed">18797453</ArticleId></ArticleIdList></Reference><Reference><Citation>Morais, P., Adachi, H. &amp; Yu, Y. T. The critical contribution of pseudouridine to mRNA COVID-19 vaccines. Front. Cell Dev. Biol.9, 789427. 10.3389/fcell.2021.789427 (2021). 10.3389/fcell.2021.789427</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.789427</ArticleId><ArticleId IdType="pmc">PMC8600071</ArticleId><ArticleId IdType="pubmed">34805188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nance, K. D. &amp; Meier, J. L. Modifications in an emergency: The role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent. Sci.7, 748–756. 10.1021/acscentsci.1c00197 (2021). 10.1021/acscentsci.1c00197</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00197</ArticleId><ArticleId IdType="pmc">PMC8043204</ArticleId><ArticleId IdType="pubmed">34075344</ArticleId></ArticleIdList></Reference><Reference><Citation>Andries, O. et al. N(1)-Methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control Release217, 337–344. 10.1016/j.jconrel.2015.08.051 (2015). 10.1016/j.jconrel.2015.08.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2015.08.051</ArticleId><ArticleId IdType="pubmed">26342664</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin, A. F., Wang, C., Marcotrigiano, J. &amp; Gehrke, L. RNAs containing modified nucleotides fail to trigger RIG-I conformational changes for innate immune signaling. mBio7, 16. 10.1128/mBio.00833-16 (2016).10.1128/mBio.00833-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00833-16</ArticleId><ArticleId IdType="pmc">PMC5030355</ArticleId><ArticleId IdType="pubmed">27651356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauger, D. M. et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl. Acad. Sci. U.S.A.116, 24075–24083. 10.1073/pnas.1908052116 (2019). 10.1073/pnas.1908052116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1908052116</ArticleId><ArticleId IdType="pmc">PMC6883848</ArticleId><ArticleId IdType="pubmed">31712433</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson, A. C. &amp; Mohr, I. Control of animal virus replication by RNA adenosine methylation. Adv. Virus Res.112, 87–114. 10.1016/bs.aivir.2022.01.002 (2022). 10.1016/bs.aivir.2022.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.aivir.2022.01.002</ArticleId><ArticleId IdType="pmc">PMC10259266</ArticleId><ArticleId IdType="pubmed">35840182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. &amp; Zhou, X. N(6)-Methyladenosine and its implications in viruses. Genom. Proteom. Bioinform.21, 695–706. 10.1016/j.gpb.2022.04.009 (2023).10.1016/j.gpb.2022.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2022.04.009</ArticleId><ArticleId IdType="pmc">PMC10787122</ArticleId><ArticleId IdType="pubmed">35835441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, G. W. &amp; Siddiqui, A. Hepatitis B virus X protein expression is tightly regulated by N6-methyladenosine modification of its mRNA. J. Virol.96, e0165521. 10.1128/JVI.01655-21 (2022). 10.1128/JVI.01655-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01655-21</ArticleId><ArticleId IdType="pmc">PMC8865537</ArticleId><ArticleId IdType="pubmed">34851655</ArticleId></ArticleIdList></Reference><Reference><Citation>Svitkin, Y. V. et al. N1-Methyl-pseudouridine in mRNA enhances translation through eIF2alpha-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res.45, 6023–6036. 10.1093/nar/gkx135 (2017). 10.1093/nar/gkx135</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx135</ArticleId><ArticleId IdType="pmc">PMC5449617</ArticleId><ArticleId IdType="pubmed">28334758</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, T. C., Scotti, P. D., Miyamura, T. &amp; Takeda, N. Latent infection of a new alphanodavirus in an insect cell line. J. Virol.81, 10890–10896. 10.1128/JVI.00807-07 (2007). 10.1128/JVI.00807-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00807-07</ArticleId><ArticleId IdType="pmc">PMC2045576</ArticleId><ArticleId IdType="pubmed">17686877</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckerle, L. D., Albarino, C. G. &amp; Ball, L. A. Flock House virus subgenomic RNA3 is replicated and its replication correlates with transactivation of RNA2. Virology317, 95–108. 10.1016/j.virol.2003.08.029 (2003). 10.1016/j.virol.2003.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2003.08.029</ArticleId><ArticleId IdType="pubmed">14675628</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher, T. M., Friesen, P. D. &amp; Rueckert, R. R. Autonomous replication and expression of RNA 1 from black beetle virus. J. Virol.46, 481–489. 10.1128/JVI.46.2.481-489.1983 (1983). 10.1128/JVI.46.2.481-489.1983</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.46.2.481-489.1983</ArticleId><ArticleId IdType="pmc">PMC255150</ArticleId><ArticleId IdType="pubmed">16789241</ArticleId></ArticleIdList></Reference><Reference><Citation>Parr, C. J. C. et al. N 1-Methylpseudouridine substitution enhances the performance of synthetic mRNA switches in cells. Nucleic Acids Res.48, e35. 10.1093/nar/gkaa070 (2020). 10.1093/nar/gkaa070</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa070</ArticleId><ArticleId IdType="pmc">PMC7102939</ArticleId><ArticleId IdType="pubmed">32090264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitlin, L., Hagai, T., LaBarbera, A., Solovey, M. &amp; Andino, R. Rapid evolution of virus sequences in intrinsically disordered protein regions. PLoS Pathog.10, e1004529. 10.1371/journal.ppat.1004529 (2014). 10.1371/journal.ppat.1004529</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004529</ArticleId><ArticleId IdType="pmc">PMC4263755</ArticleId><ArticleId IdType="pubmed">25502394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, J. Y. et al. Viral and host proteins involved in picornavirus life cycle. J. Biomed. Sci.16, 103. 10.1186/1423-0127-16-103 (2009). 10.1186/1423-0127-16-103</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-16-103</ArticleId><ArticleId IdType="pmc">PMC2785775</ArticleId><ArticleId IdType="pubmed">19925687</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey, J. M. &amp; Tapprich, W. E. Structure of the 5’ nontranslated region of the coxsackievirus b3 genome: Chemical modification and comparative sequence analysis. J. Virol.81, 650–668. 10.1128/JVI.01327-06 (2007). 10.1128/JVI.01327-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01327-06</ArticleId><ArticleId IdType="pmc">PMC1797431</ArticleId><ArticleId IdType="pubmed">17079314</ArticleId></ArticleIdList></Reference><Reference><Citation>Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther.23, 1456–1464. 10.1038/mt.2015.103 (2015). 10.1038/mt.2015.103</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2015.103</ArticleId><ArticleId IdType="pmc">PMC4817881</ArticleId><ArticleId IdType="pubmed">26050989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft, R. A. et al. RNA circularization diminishes immunogenicity and can extend translation duration in vivo. Mol. Cell74, 508–520. 10.1016/j.molcel.2019.02.015 (2019). 10.1016/j.molcel.2019.02.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2019.02.015</ArticleId><ArticleId IdType="pmc">PMC6724735</ArticleId><ArticleId IdType="pubmed">30902547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kameda, S., Ohno, H. &amp; Saito, H. Synthetic circular RNA switches and circuits that control protein expression in mammalian cells. Nucleic Acids Res.51, e24. 10.1093/nar/gkac1252 (2023). 10.1093/nar/gkac1252</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1252</ArticleId><ArticleId IdType="pmc">PMC9976894</ArticleId><ArticleId IdType="pubmed">36642090</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietila, M. K., Hellstrom, K. &amp; Ahola, T. Alphavirus polymerase and RNA replication. Virus Res.234, 44–57. 10.1016/j.virusres.2017.01.007 (2017). 10.1016/j.virusres.2017.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2017.01.007</ArticleId><ArticleId IdType="pubmed">28104453</ArticleId></ArticleIdList></Reference><Reference><Citation>Westhof, E. Pseudouridines or how to draw on weak energy differences. Biochem. Biophys. Res. Commun.520, 702–704. 10.1016/j.bbrc.2019.10.009 (2019). 10.1016/j.bbrc.2019.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.10.009</ArticleId><ArticleId IdType="pubmed">31761086</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulroney, T. E. et al. N(1)-Methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature625, 189–194. 10.1038/s41586-023-06800-3 (2024). 10.1038/s41586-023-06800-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06800-3</ArticleId><ArticleId IdType="pmc">PMC10764286</ArticleId><ArticleId IdType="pubmed">38057663</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakney, A. K. et al. Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA. Mol. Ther.29, 1174–1185. 10.1016/j.ymthe.2020.11.011 (2021). 10.1016/j.ymthe.2020.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.11.011</ArticleId><ArticleId IdType="pmc">PMC7935664</ArticleId><ArticleId IdType="pubmed">33352107</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkovic, M. et al. A trans-amplifying RNA simplified to essential elements is highly replicative and robustly immunogenic in mice. Mol. Ther.31, 1636–1646. 10.1016/j.ymthe.2023.01.019 (2023). 10.1016/j.ymthe.2023.01.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2023.01.019</ArticleId><ArticleId IdType="pmc">PMC10277886</ArticleId><ArticleId IdType="pubmed">36694464</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida, A. et al. Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. iScience25, 105412. 10.1016/j.isci.2022.105412 (2022). 10.1016/j.isci.2022.105412</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105412</ArticleId><ArticleId IdType="pmc">PMC9614708</ArticleId><ArticleId IdType="pubmed">36320329</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh, M. T. et al. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature619, 135–142. 10.1038/s41586-023-06212-3 (2023). 10.1038/s41586-023-06212-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06212-3</ArticleId><ArticleId IdType="pmc">PMC10322712</ArticleId><ArticleId IdType="pubmed">37316671</ArticleId></ArticleIdList></Reference><Reference><Citation>Komori, M. et al. Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine. BioRxiv.10.1101/2023.11.01.565056 (2023). 10.1101/2023.11.01.565056</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.01.565056</ArticleId><ArticleId IdType="pmc">PMC10634970</ArticleId><ArticleId IdType="pubmed">37961509</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboshi, M. et al. Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine. iScience27, 108964. 10.1016/j.isci.2024.108964 (2024). 10.1016/j.isci.2024.108964</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.108964</ArticleId><ArticleId IdType="pmc">PMC10863314</ArticleId><ArticleId IdType="pubmed">38352232</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold, J. &amp; Andino, R. Poliovirus requires a precise 5’ end for efficient positive-strand RNA synthesis. J. Virol.74, 6394–6400. 10.1128/jvi.74.14.6394-6400.2000 (2000). 10.1128/jvi.74.14.6394-6400.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.14.6394-6400.2000</ArticleId><ArticleId IdType="pmc">PMC112146</ArticleId><ArticleId IdType="pubmed">10864650</ArticleId></ArticleIdList></Reference><Reference><Citation>Vignuzzi, M., Gerbaud, S., van der Werf, S. &amp; Escriou, N. Expression of a membrane-anchored glycoprotein, the influenza virus hemagglutinin, by dicistronic replicons derived from the poliovirus genome. J. Virol.76, 5285–5290. 10.1128/jvi.76.10.5285-5290.2002 (2002). 10.1128/jvi.76.10.5285-5290.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.76.10.5285-5290.2002</ArticleId><ArticleId IdType="pmc">PMC136135</ArticleId><ArticleId IdType="pubmed">11967344</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer, R. G. et al. Plasmid-based generation of recombinant coxsackievirus B3 particles carrying capsid gene replacement replicons. Virus Res.104, 17–26. 10.1016/j.virusres.2004.02.037 (2004). 10.1016/j.virusres.2004.02.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2004.02.037</ArticleId><ArticleId IdType="pubmed">15177888</ArticleId></ArticleIdList></Reference><Reference><Citation>Quirin, T., Chen, Y., Pietila, M. K., Guo, D. &amp; Ahola, T. The RNA capping enzyme domain in protein A is essential for flock house virus replication. Viruses10, 483. 10.3390/v10090483 (2018). 10.3390/v10090483</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10090483</ArticleId><ArticleId IdType="pmc">PMC6165433</ArticleId><ArticleId IdType="pubmed">30205593</ArticleId></ArticleIdList></Reference><Reference><Citation>Liljestrom, P. &amp; Garoff, H. A new generation of animal-cell expression vectors based on the semliki forest virus replicon. Bio-Technology9, 1356–1361. 10.1038/nbt1291-1356 (1991). 10.1038/nbt1291-1356</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1291-1356</ArticleId><ArticleId IdType="pubmed">1370252</ArticleId></ArticleIdList></Reference><Reference><Citation>Warncke, S. R. &amp; Knudsen, C. R. Detection methods targeting the positive- and negative-sense RNA transcripts from plus-stranded RNA viruses. APMIS130, 284–292. 10.1111/apm.13202 (2022). 10.1111/apm.13202</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.13202</ArticleId><ArticleId IdType="pmc">PMC9306919</ArticleId><ArticleId IdType="pubmed">34939239</ArticleId></ArticleIdList></Reference><Reference><Citation>Oyama, R. et al. An ionizable lipid material with a vitamin E scaffold as an mRNA vaccine platform for efficient cytotoxic T cell responses. ACS Nano17, 18758–18774. 10.1021/acsnano.3c02251 (2023). 10.1021/acsnano.3c02251</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.3c02251</ArticleId><ArticleId IdType="pmc">PMC10569098</ArticleId><ArticleId IdType="pubmed">37814788</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>